Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, El-Galaly TC, Kugathasan L, Scott DW, Gerrie AS, Lewis D. Villa D, et al. Among authors: buege mj. Blood Adv. 2023 Aug 22;7(16):4576-4585. doi: 10.1182/bloodadvances.2023009804. Blood Adv. 2023. PMID: 37307169 Free PMC article.
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. Sawalha Y, et al. Blood Adv. 2023 Jul 11;7(13):2983-2993. doi: 10.1182/bloodadvances.2022008916. Blood Adv. 2023. PMID: 36809796 Free PMC article.
Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.
Buege MJ, Kumar A, Dixon BN, Tang LA, Pak T, Orozco J, Peterson TJ, Maples KT. Buege MJ, et al. Ann Pharmacother. 2020 Sep;54(9):879-898. doi: 10.1177/1060028020909117. Epub 2020 Feb 20. Ann Pharmacother. 2020. PMID: 32079411 Free PMC article. Review.
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
Pak TK, Dixon BN, Buege MJ, Dao PH, Leary MH, Jarrett JC, Duggan TA, Caron P, Falchi L, Hamlin P, Hamilton A, Matasar MJ, Moskowitz A, Noy A, Owens CN, Von Keudell G, Younes A, Zelenetz AD, Kumar A. Pak TK, et al. Among authors: buege mj. Leuk Lymphoma. 2022 Apr;63(4):876-884. doi: 10.1080/10428194.2021.2002318. Epub 2021 Nov 16. Leuk Lymphoma. 2022. PMID: 34784853
Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City.
Yerram P, Thackray J, Modelevsky LR, Land JD, Reiss SN, Spatz KH, Levoir AC, Pak TK, Dao PH, Buege MJ, Derespiris LM, Lau C, Orozco JS, Boparai M, Koranteng LA, Reichert KE, Yan SQ, Daukshus NP, Mathew S, Buie LW, Tizon RF, Freeswick S, Liu D, Harnicar S. Yerram P, et al. Among authors: buege mj. J Oncol Pharm Pract. 2021 Mar;27(2):389-394. doi: 10.1177/1078155220987625. Epub 2021 Jan 17. J Oncol Pharm Pract. 2021. PMID: 33459159 Free PMC article.
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Qualls DA, Lambert N, Caimi PF, Merrill M, Pullarkat P, Godby RC, Bond DA, Wehmeyer GT, Romancik J, Amoozgar B, Leslie L, Nastoupil LJ, Crombie JL, Abramson JS, Khurana A, Nowakowski GS, Maddocks K, Rutherford SC, Kahl B, Okwali M, Buege MJ, Seshan V, Batlevi CL, Salles G. Qualls DA, et al. Among authors: buege mj. Blood. 2023 Dec 28;142(26):2327-2331. doi: 10.1182/blood.2023021274. Blood. 2023. PMID: 37738563
12 results